AnaptysBio, Inc. (LON:0HFQ)
36.36
-0.18 (-0.50%)
At close: Oct 31, 2025
AnaptysBio Revenue
AnaptysBio had revenue of $22.26M USD in the quarter ending June 30, 2025, with 102.93% growth. This brings the company's revenue in the last twelve months to $123.16M, up 304.17% year-over-year. In the year 2024, AnaptysBio had annual revenue of $91.28M with 432.03% growth.
Revenue (ttm)
$123.16M
Revenue Growth
+304.17%
P/S Ratio
8.67
Revenue / Employee
$905.62K
Employees
136
Market Cap
779.75M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 91.28M | 74.12M | 432.03% |
| Dec 31, 2023 | 17.16M | 6.87M | 66.78% |
| Dec 31, 2022 | 10.29M | -52.89M | -83.72% |
| Dec 31, 2021 | 63.18M | -11.83M | -15.77% |
| Dec 31, 2020 | 75.00M | 67.00M | 837.50% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Shell | 200.18B |
| BP p.l.c. | 134.89B |
| Unilever | 51.24B |
| HSBC Holdings | 43.13B |
| AstraZeneca | 41.24B |
| Rio Tinto Group | 39.22B |
| GSK plc | 32.17B |
| Barclays | 26.03B |